Moreover, pancreatic cancer generally exhibits a lower mutation load compared with other solid tumors, and therefore, PD-1/PD-L1 blockade is usually ineffective for those patients and fails to improve their survival outcomes. Here, CD274 is linked to familial pancreatic carcinoma.